Did you receive the October 2025 COVID booster?
The updated booster was designed for strains circulating before BA.3.2 emerged.
The October booster has under 12% efficacy against BA.3.2 Cicada.
BA.3.2 carries 75 spike protein mutations compared to the strains the 2025-2026 booster was designed for. Omicron had 32. Cicada has more than double.
The vaccine was manufactured before this variant emerged. By the time BA.3.2 was identified, 180 million doses were already in arms — built for a virus that had already moved on.
8% efficacy · 75 mutations · Vaccine mismatch confirmedHave you ever had COVID-19 — any variant, any time?
Prior infection affects your nasal defense barrier status.
Prior COVID infection degrades your nasal defense by up to 73%.
The virus that infected you also damaged the nasal epithelium — the mucosal tissue lining inside your nose that serves as the body's first barrier against every airborne pathogen. The mucosal lining thins. The cilia are damaged. Local antibody production is suppressed.
Prior infection doesn't make you stronger. It makes you more vulnerable. The door the virus walked through the first time is now broken open for the next one.
73% nasal defense degradation post-COVIDHave you experienced any of the following in the past 14 days?
Select all that apply
Which of these are part of your weekly routine?
Select all that apply
Which age group applies to you?
Age is a primary variable in Cicada variant risk stratification.
Every respiratory virus enters through the nose. Nothing in your medicine cabinet guards that entry point.
BA.3.2 Cicada — like every COVID variant, every flu strain, every RSV case — enters through the nasal cavity. It attaches to the mucosal tissue. It replicates for 2 to 4 days before you feel anything. By the time you feel the sore throat, the virus has had a 72-hour head start.
The flu shot, vitamins, zinc, saline, Flonase — none of them kill the virus where it enters. They operate in the bloodstream or manage symptoms after infection is established. Zero protection at the nasal entry point.
0 of your current defenses guard the nasal entry pointWhich preventive measures do you currently rely on?
Select all that apply
Do you have regular contact with anyone over 60, immunocompromised, or with chronic health conditions?
Do you have any chronic health conditions?
Select all that apply
How concerned are you about catching the Cicada variant?
If a clinically validated, 10-second daily nasal defense could reduce your risk of Cicada infection — would you use it?
Generating your Cicada risk assessment…
Assessment: Your nasal passages are currently unprotected against the BA.3.2 Cicada variant.
Your responses indicate multiple compounding risk factors — including booster mismatch (8% efficacy against Cicada), potential nasal defense degradation from prior COVID infection, age-related vulnerability, and reliance on preventive measures that do not address the nasal entry point where every respiratory virus enters.
Recommended: Nasal Iodine Defense Protocol
A growing number of ER physicians and ICU nurses use povidone-iodine nasal spray — the same hospital-grade antiseptic used in surgical preparation for 100+ years — applied directly to the nasal passages. Peer-reviewed research shows it neutralizes 99% of respiratory viruses within 90 seconds at the entry point. Works on every variant. Every mutation. No resistance possible. 10 seconds, twice daily. No prescription required.